Description
Assess Risk of Ovarian Cancer in Women with Ovarian Masses
The ROMA test is a clinically validated diagnostic tool that calculates the likelihood of ovarian cancer in women who present with an ovarian mass. It combines two key blood biomarkers with a patient’s menopausal status to generate a personalized risk score, helping to guide further clinical decisions.
Purpose of the ROMA Test
- Evaluate the risk of malignancy in ovarian masses.
- Distinguish between benign and malignant tumors.
- Support triage and referral decisions, especially to gynecologic oncologists.
- Assist in determining the need for additional imaging, biopsy, or surgery.
How the ROMA Test Works
Biomarkers Measured
- HE4 (Human Epididymis Protein 4)
- Often elevated in ovarian cancer.
- Offers higher specificity compared to CA125.
- CA125 (Cancer Antigen 125)
- A commonly used ovarian cancer biomarker.
- Can also be elevated in non-cancerous conditions like endometriosis or fibroids.
Menopausal Status
- The algorithm adjusts interpretation based on whether the patient is pre-menopausal or post-menopausal, as hormone levels and biomarker thresholds differ between the two.
ROMA Score Calculation
- Combines levels of HE4, CA125, and menopausal status.
- Results yield a numerical ROMA score that stratifies cancer risk:
- Low ROMA Score → Low risk of malignancy
- High ROMA Score → Elevated risk of ovarian cancer; further workup may be necessary
Key Benefits
- Higher Accuracy: More reliable than CA125 alone for detecting malignancy.
- Non-Invasive: Simple blood draw with no special preparation needed.
- Clinically Actionable: Helps determine the next steps in diagnosis and treatment planning.
- Personalized Assessment: Tailored to menopausal status for better risk estimation.
Fasting Requirements
- Not required — the test can be performed at any time of day.
Who Should Consider the ROMA Test?
- Women with an identified ovarian mass
- Patients needing risk stratification before surgery or further imaging
- Providers seeking to optimize referral decisions to specialists